Additional Administration Option Approved for Nuplazid Capsules
Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson disease psychosis.
Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson disease psychosis.
Physicians should carefully weigh the risks against the potential benefits before prescribing anticholinergics, according to investigators.
Dementia risk did not differ by general, regional anesthesia in seniors undergoing elective surgery.
Cognitive decline slower, dementia risk reduced in seniors with diabetes receiving metformin
Overall, Rx filled for antidepressants in 49.8 percent, opioids in 29.8 percent, anxiolytics in 26.8 percent
The FDA has accepted for filing the supplemental New Drug Application (sNDA) for pimavanserin (Nuplazid®; Acadia) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
Acadia Pharmaceuticals has submitted a supplemental New Drug Application to the FDA for pimavanserin (Nuplazid®) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
Previous research has suggested that treatment with metformin may potentially lower the risk of dementia, however whether the timing of treatment impacts this result remains unclear.
Among patients with overactive bladder (OAB), anticholinergic medication use appears to be associated with an increased risk of new onset dementia when compared with beta-3 agonist use, according to the findings of a retrospective population-based cohort study.
The FDA has granted Fast Track designation to PR006 (Prevail Therapeutics), an experimental gene therapy, to slow the progression of frontotemporal dementia with a GRN mutation.